🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

HMJ acquires health research firm CAMRIS International

The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) has acquired CAMRIS International, a Maryland-based international development and health research firm.

CAMRIS is said to combine research and technical assistance expertise of 250 plus employees with modern, evidence-based practices for developing innovative solutions for complex problems.

With experience spread over all regions of the globe, CAMRIS’ main focus is on military medical research and global health.

Dr. Joseph Caravalho – HJF President and CEO said: “As a trusted partner in military medicine, HJF continuously looks to improve our ability to deliver the best service possible to those conducting medical research benefitting our nation’s warfighters and civilians alike.

“This acquisition bolsters HJF’s broader capabilities due to the CAMRIS team’s success in delivering requirements-driven results on contracts worldwide.”

HMJ acquires health research firm CAMRIS International
HMJ acquires health research firm CAMRIS International. Photo courtesy of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

CAMRIS is now a fully-owned subsidiary of HJF. The new board of directors of the company will be made of representatives from CAMRIS and also HJF.

Dr. Laurence M. Day – CAMRIS President and CEO said: “CAMRIS has more than 60 years of experience providing agile and adaptable solutions to research partners around the globe.

“CAMRIS is excited to join HJF, a leader in advancing medical research worldwide. We have previously worked in partnership with HJF, and by deepening the strong alignment of the HJF and CAMRIS missions, this acquisition will produce many benefits for each organization, as well as our collective customers and partners.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Related Posts
Read More

Thyme Care crosses $2bn valuation as $7bn oncology platform expands into new businesses

Thyme Care has secured more than $125 million from Morgan Health, Humana, CVS Health Ventures and other investors at a valuation above $2 billion. The company is already profitable, reaches 10.5 million people and manages more than $7 billion of oncology spending. Its next move is more ambitious: turning the cancer-care platform into a parent company that can attack drug costs, biosimilar adoption and clinical-trial access.